

CONEXXENCE® (denosumab-bnht)
Injection for subcutaneous use

Billing & Coding Guide

Important Safety Information

SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE:

Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia. Prior to initiating Conexxence in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Conexxence in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD.

Please see additional Important Safety Information throughout this brochure and click to see [Full Prescribing Information](#) and Medication Guide, including **Boxed Warning** for CONEXXENCE® (denosumab-bnht).

CONEXXENCE® (denosumab-bnht) Billing and Coding Guide

The CONEXXENCE® Billing and Coding Guide provides general reimbursement information for healthcare providers.

Topics include billing, coding, coverage, and reimbursement for treatment with CONEXXENCE®.

The content provided in this guide is for informational purposes only and is not intended as legal advice or to replace a medical provider's professional judgment. It is the sole responsibility of the treating healthcare professional to confirm coverage, coding, and claim submission guidance with the patient's health insurance plan to ensure CONEXXENCE® claims are accurate, complete, and supported by documentation in the patient's medical record. Fresenius Kabi does not guarantee that payers will consider all codes appropriate for all encountered scenarios and Fresenius Kabi does not guarantee CONEXXENCE® coverage or reimbursement.



Contact your Account Manager to connect with a Field Reimbursement Manager for the latest payer coverage for patients and assistance with billing and coding.

Important Safety Information

CONTRAINDICATIONS

Patients with hypocalcemia

Pre-existing hypocalcemia must be corrected prior to initiating therapy with Conexxence.

Pregnant women

Denosumab products may cause fetal harm when administered to a pregnant woman. In women of reproductive potential, pregnancy testing should be performed prior to initiating treatment with Conexxence.

Patients with hypersensitivity to denosumab products

Conexxence is contraindicated in patients with a history of systemic hypersensitivity to any component of the product. Reactions have included anaphylaxis, facial swelling, and urticaria.

WARNINGS AND PRECAUTIONS

Severe Hypocalcemia and Mineral Metabolism Changes

Denosumab products can cause severe hypocalcemia and fatal cases have been reported. Preexisting hypocalcemia must be corrected

prior to initiating therapy with Conexxence. Adequately supplement all patients with calcium and vitamin D.

In patients without advanced chronic kidney disease who are predisposed to hypocalcemia and disturbances of mineral metabolism, assess serum calcium and mineral levels (phosphorus and magnesium) 10 to 14 days after Conexxence injection. In some postmarketing cases, hypocalcemia persisted for weeks or months and required frequent monitoring and intravenous and/or oral calcium replacement, with or without vitamin D.

Patients with Advanced Chronic Kidney Disease

Patients with advanced chronic kidney disease [i.e., eGFR < 30 mL/min/1.73 m²] including dialysis-dependent patients are at greater risk for severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. The presence of underlying chronic kidney disease-mineral bone disorder (CKD-MBD, renal osteodystrophy) markedly increases the risk of hypocalcemia. Concomitant use of calcimimetic drugs may also worsen hypocalcemia risk.

Please see additional Important Safety Information throughout this brochure and click to see [Full Prescribing Information](#) and Medication Guide, including **Boxed Warning** for CONEXXENCE® (denosumab-bnht).


Indications/Formulation

INDICATIONS AND USAGE¹

CONEXXENCE® (denosumab-bnht) is indicated for treatment:

- of postmenopausal women with osteoporosis at high risk for fracture
- to increase bone mass in men with osteoporosis at high risk for fracture
- of glucocorticoid-induced osteoporosis in men and women at high risk for fracture
- to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
- to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer

Available as a single-dose prefilled syringe¹



60 mg/mL

NDC # 65219-668-01

Important Safety Information (continued)

To minimize the risk of hypocalcemia in patients with advanced chronic kidney disease, evaluate for the presence of chronic kidney disease mineral and bone disorder with intact parathyroid hormone (iPTH), serum calcium, 25(OH) vitamin D, and 1,25(OH)₂ vitamin D prior to decisions regarding Conexxence treatment. Consider also assessing bone turnover status (serum markers of bone turnover or bone biopsy) to evaluate the underlying bone disease that may be present. Monitor serum calcium weekly for the first month after Conexxence administration and monthly thereafter. Instruct all patients with advanced chronic kidney disease, including those who are dialysis-dependent, about the symptoms of hypocalcemia and the importance of maintaining serum calcium levels with adequate calcium and activated vitamin D supplementation. Treatment with Conexxence in these patients should be supervised by a healthcare provider who is experienced in diagnosis and management of CKD-MBD.

Drug Products with Same Active Ingredient

Patients receiving Conexxence should not receive other denosumab products concomitantly.

Hypersensitivity

Clinically significant hypersensitivity including anaphylaxis has been reported with denosumab products. Symptoms have included hypotension, dyspnea, throat tightness, facial and upper airway edema, pruritus, and urticaria. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of Conexxence.

Osteonecrosis of the Jaw (ONJ)

ONJ, which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing. ONJ has been reported in patients receiving denosumab products. An oral

ICD-10

This coding information may assist you as you complete the payer forms for CONEXXENCE® (denosumab-bnht).

ICD-10-CM Codes² for Consideration*

Osteoporosis

M80.0	Age-related osteoporosis with current pathological fracture
M81.0	Age-related osteoporosis without current pathological fracture
M81.8	Other osteoporosis without current pathological fracture

Cancer Treatment-Induced Bone Loss

C61.0	Malignant neoplasm of prostate
M85.9	Disorder of bone density and structure, unspecified
M81.0	Age-related osteoporosis without current pathologic fracture
M81.8	Other osteoporosis without pathologic fracture
M80.0	Age-related osteoporosis with current pathologic fracture
M80.8	Other osteoporosis with current pathological fracture

* ICD-10-CM diagnosis codes consist of 3 to 7 alphanumeric characters, providing increasing levels of specificity. A 3-character code is appropriate only when there is no need for additional subdivision. A code is invalid if it has not been coded to the full number of characters required for that code.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care, and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Fresenius Kabi does not make any representation or guarantee concerning reimbursement or coverage for any item or service. Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Important Safety Information

exam should be performed by the prescriber prior to initiation of Conexence. A dental examination with appropriate preventive dentistry is recommended prior to treatment with Conexence in patients with risk factors for ONJ such as invasive dental procedures, diagnosis of cancer, concomitant therapies (e.g. chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and comorbid disorders. Good oral hygiene practices should be maintained during treatment with Conexence. Concomitant administration of drugs associated with ONJ may increase the risk of developing ONJ. The risk of ONJ may increase with duration of exposure to denosumab products.

For patients requiring invasive dental procedures, clinical judgment should guide the management plan of each patient. Patients who are suspected of having or who develop ONJ while on Conexence should receive care by a dentist or an oral surgeon. Extensive dental

surgery to treat ONJ may exacerbate the condition. Discontinuation of Conexence therapy should be considered based on individual benefit-risk assessment.

Atypical Subtrochanteric and Diaphyseal Femoral Fractures

Atypical low energy or low trauma fractures of the shaft have been reported in patients receiving denosumab products. Causality has not been established as these fractures also occur in osteoporotic patients who have not been treated with antiresorptive agents. During Conexence treatment, patients should be advised to report new or unusual thigh, hip, or groin pain. Any patient who presents with thigh or groin pain should be suspected of having an atypical fracture and should be evaluated to rule out an incomplete femur fracture. Interruption of Conexence therapy should be considered, pending a benefit-risk assessment, on an individual basis.

Please see additional Important Safety Information throughout this brochure and click to see [Full Prescribing Information](#) and Medication Guide, including **Boxed Warning** for CONEXXENCE® (denosumab-bnht).

Healthcare Common Procedure Coding System (HCPCS)

HCPCS Code for CONEXXENCE® (denosumab-bnht)³

Code	Description	Site of Service	Billing Units
Q5158	Injection, denosumab-bnht (BOMYNTRA/ CONEXXENCE), biosimilar, 1 mg	All	1 mg

Inaccurate reporting of drug billing units is a common claims error and can result in denied or delayed payment.

Important Safety Information

Multiple Vertebral Fractures (MVF) Following Discontinuation of Treatment

Following discontinuation of denosumab treatment, fracture risk increases, including the risk of multiple vertebral fractures. New vertebral fractures occurred as early as 7 months (on average 19 months) after the last dose of denosumab. Prior vertebral fracture was a predictor of multiple vertebral fractures after denosumab discontinuation. Evaluate an individual's benefit-risk before initiating treatment with Conexxence. If Conexxence treatment is discontinued, patients should be transitioned to an alternative antiresorptive therapy.

Serious Infections

In a clinical trial of over 7800 women with postmenopausal osteoporosis, serious infections leading to hospitalization were reported

more frequently in the denosumab group than in the placebo group. Serious skin infections, as well as infections of the abdomen, urinary tract, and ear, were more frequent in patients treated with denosumab. Endocarditis was also reported more frequently in denosumab-treated patients. The incidence of opportunistic infections was similar between placebo and denosumab groups, and the overall incidence of infections was similar between the treatment groups. Advise patients to seek prompt medical attention if they develop signs or symptoms of severe infection, including cellulitis.

Patients on concomitant immunosuppressant agents or with impaired immune systems may be at increased risk for serious infections. In patients who develop serious infections while on Conexxence, prescribers should assess the need for continued Conexxence therapy.

Modifiers

Summary of Code Modifiers				
Modifier	Description ⁴	Indication and Placement ^{5,6}	CMS-1500 (Item 24D)	CMS-1450 (Box 44)
JW	Drug amount discarded/not administered to any patient	Applies only to the unused drug that is discarded after applicable dose has been administered from a single-use vial.	✓ Required by Medicare	✓ Required by Medicare
JZ	Zero drug amount discarded/not administered to any patient	To be used for single-dose containers or single-use packages when the entire amount has been administered to the patient (no wastage).	✓ Required by Medicare	✓ Required by Medicare
TB	Drug or biological acquired with 340B Drug Pricing Program discount, reported for informational purposes for select entities	TB modifier is used to identify drugs or biologicals acquired through the 340B Drug Pricing Program for informational purposes. The TB modifier is required for all 340B covered entities, including hospital-based and non-hospital-based entities, for claims with dates of service beginning on or after January 1, 2025. TB modifier to be reported on the same claim line as the drug HCPCS code for all 340B acquired drugs.	N/A	✓ Required by Medicare

When using miscellaneous code, amount wasted is captured in CMS 1500 Form Block 19 & CMS 1450 Form FL 80, and claim form should not include separate line for JW.

Important Safety Information (continued)

Dermatologic Adverse Reactions

In a clinical trial of over 7800 women with postmenopausal osteoporosis, epidermal and dermal adverse events such as dermatitis, eczema, and rashes occurred at a significantly higher rate in the denosumab group compared to the placebo group. Most of these events were not specific to the injection site. Consider discontinuing Conexence if severe symptoms develop.

Musculoskeletal Pain

Severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients taking denosumab products. Consider discontinuing use if severe symptoms develop.

Suppression of Bone Turnover

Treatment with denosumab resulted in significant suppression of bone remodeling as evidenced by markers of bone turnover and bone histomorphometry. The significance of these findings and the effect of

long-term treatment with denosumab products are unknown. Monitor patients for consequences, including ONJ, atypical fractures, and delayed fracture healing.

Hypercalcemia in Pediatric Patients with Osteogenesis Imperfecta

Conexence is not approved for use in pediatric patients. Hypercalcemia has been reported in pediatric patients with osteogenesis imperfecta treated with denosumab products. Some cases required hospitalization.

ADVERSE REACTIONS

The most common adverse reactions reported with denosumab products in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis. The most common adverse reactions leading to discontinuation of denosumab products in patients with postmenopausal osteoporosis are back pain and constipation. The most common adverse reactions reported with denosumab products in men with osteoporosis are back pain, arthralgia, and nasopharyngitis. Pancreatitis has been

Please see additional Important Safety Information throughout this brochure and click to see [Full Prescribing Information](#) and Medication Guide, including **Boxed Warning** for CONEXENCE® (denosumab-bnht).

NDC Numbers and CPT Codes



What codes do I use to bill for CONEXXENCE® (denosumab-bnht)?

- A new prescription is required for CONEXXENCE®.
- To ensure your patient will receive CONEXXENCE®, please select the appropriate dosing when prescribing.

National Drug Code (NDC)¹

Electronic data exchange standards usually require the use of an 11-digit NDC. Check with the payer to confirm the correct code required when billing for CONEXXENCE®.

Dosage Form	Description	10-digit NDC Code	11-digit NDC Code
SC Injection	60 mg/mL	65219-668-01	65219-0668-01

Current Procedural Terminology (CPT) Code^{7,8}

CPT codes are the standard coding system for reporting medical procedures and services under both public and private health insurance plans.

Type	Code	Description
CPT Code–SC injection	96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular.
	96401	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal antineoplastic

All coding and documentation requirements should be confirmed with each payer before submitting a claim for reimbursement.

Important Safety Information (continued)

reported with denosumab. The overall incidence of new malignancies in postmenopausal women with osteoporosis was 4.3% in the placebo and 4.8% in the denosumab groups, and in men with osteoporosis, no patients in the placebo group and 3.3% in the denosumab group. A causal relationship to drug exposure has not been established.

The most common adverse reactions reported with denosumab products in patients with glucocorticoid-induced osteoporosis are back pain, hypertension, bronchitis, and headache.

The most common adverse reactions reported with denosumab products in patients with bone loss receiving ADT for prostate cancer or adjuvant AI therapy for breast cancer are arthralgia and back pain. Pain in extremity and musculoskeletal pain have also been reported in clinical trials. Additionally, in denosumab-treated men with nonmetastatic prostate cancer receiving ADT, a greater incidence of cataracts was observed.

INDICATIONS

Conexxence (denosumab-bnht) is indicated for treatment:

- of postmenopausal women with osteoporosis at high risk for fracture
- to increase bone mass in men with osteoporosis at high risk for fracture
- of glucocorticoid-induced osteoporosis in men and women at high risk for fracture
- to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
- to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer

Please see Conexxence full Prescribing Information and Medication Guide.

Please see additional Important Safety Information throughout this brochure and click to see [Full Prescribing Information](#) and Medication Guide, including **Boxed Warning** for CONEXXENCE® (denosumab-bnht).

Physician's Office Billing Information⁹

CONEXXENCE[®] (denosumab-bnht) Coding Information*

Coding Information in **Block 24D:**
(Electronic Form: Loop 2400, SV1, 01-2)

Input HCPCS code Q5158 and required modifiers on separate lines.

Number of Units in **Block 24G:**
(Electronic Form: Loop 2400, SV1, 04 [03 = UN])

Enter the amount administered. Denosumab-bnht is billed in 1 mg units. Each 60 mg dose of CONEXXENCE is billed as 60 units.

Administration and Professional Service Coding Information*

Coding Information in **Block 24D:**
(Electronic Form: Loop 2400, SV1, 01-2)

Enter appropriate CPT code and Modifier if applicable.

Diagnosis Code Information*

ICD-10-CM Code in Block 21:
(Electronic Form: Loop 2300, HI, 01-2)

Indicate diagnosis using appropriate ICD-10 CM codes. Use diagnosis codes to highest level of specificity for the date of service, and enter the diagnosis in priority order.

* The sample codes are informational and not intended to be directive or a guarantee of reimbursement and include potential codes that would include FDA-approved indications for CONEXXENCE[®]. Other codes may be more appropriate given internal system guidelines, payer requirements, practice patterns, and the services rendered.

These sample claim forms are for informational purposes only and are not intended to replace a medical provider's professional judgment. It is the sole responsibility of the treating healthcare provider to confirm coverage, coding, and claim submission guidance with the patient's health insurance plan to ensure CONEXXENCE® (denosumab-bnht) claims are accurate, complete, and supported by documentation in the patient's medical record. Fresenius Kabi does not guarantee CONEXXENCE® coverage or reimbursement.

Please see additional Important Safety Information throughout this brochure and click to see [Full Prescribing Information](#) and Medication Guide, including **Boxed Warning** for CONEXXENCE® (denosumab-bnht).

Hospital/Institutional Billing¹⁰

CONEXXENCE® (denosumab-bnht) Coding Information*

Revenue Code in Form Location (FL) 42: (Electronic Form: Loop 2400, SV201)	List revenue codes in ascending order.
Coding Information in FL 44: (Electronic Form: Loop 2400, SV202-2 [SV202-1=HC/HP])	Enter appropriate HCPCS/Modifiers and CPT codes. Q5158–Injection, denosumab-bnht (BOMYNTRA/CONEXXENCE), biosimilar, 1 mg.
Service Units in FL 46: (Electronic Form: Loop 2400, SV205)	Enter the amount administered. Denosumab-bnht is billed in 1 mg units. Each 60 mg dose of CONEXXENCE is billed as 60 units.

Administration and Professional Service Coding Information*

Revenue Code in FL 42: (Electronic Form: Loop 2400, SV201)	Enter appropriate revenue code for the cost center in which the service is performed.
Description in FL 43: (Not required by Medicare)	Enter narrative description of corresponding revenue code (e.g., clinic, lab, infusion).
Coding Information in FL 44: (Electronic Form: Loop 2400, SV202-2 [SV202-1=HC/HP])	Enter appropriate CPT code and Modifier if applicable.

Diagnosis Code Information*

ICD-10-CM Code in FL 67: (Electronic Form: Loop 2300, HI01-2 [HI01-1=BK])	Enter appropriate ICD-10-CM code(s) for patient condition. Sequencing of codes may vary based on patient's condition and payer's policy.
--	---

* The sample codes are informational and not intended to be directive or a guarantee of reimbursement and include potential codes that would include FDA-approved indications for CONEXXENCE®. Other codes may be more appropriate given internal system guidelines, payer requirements, practice patterns, and the services rendered.

The JW and JZ modifier requirement applies to all separately payable drugs from single-dose containers assigned status indicators "G" (pass-through drugs and biologicals) or "K" (non-pass-through drugs) under the OPPS for which there is a discarded amount.

Sample CMS 1450 (UB-04) Claim Form (hospital outpatient site of service)¹⁰

These sample claim forms are for informational purposes only and are not intended to replace a medical provider's professional judgment. It is the sole responsibility of the treating healthcare provider to confirm coverage, coding, and claim submission guidance with the patient's health insurance plan to ensure CONEXXENCE® (denosumab-bnht) claims are accurate, complete, and supported by documentation in the patient's medical record. Fresenius Kabi does not guarantee CONEXXENCE® coverage or reimbursement.

1. PATIENT NAME		2. PATIENT ADDRESS		3. PAT. CONT. # B. MED. REC. # 5. FED. TAX NO.		4. TYPE OF BILL	
8. PATIENT NAME		9. PATIENT ADDRESS		10. BIRTHDATE		11. SEX	
12. DATE		13. HR		14. TYPE		15. SRC	
16. DHR		17. STAT		18. 19		20. 21	
22. 23		24. 25		26. 27		28. 29	
30. 31		32. 33		34. 35		36. 37	
38. 39		40. 41		42. 43		44. 45	
46. 47		48. 49		50. 51		52. 53	
54. 55		56. 57		58. 59		60. 61	
62. 63		64. 65		66. 67		68. 69	
70. 71		72. 73		74. 75		76. 77	
78. 79		80. 81		82. 83		84. 85	
86. 87		88. 89		90. 91		92. 93	
94. 95		96. 97		98. 99		100. 101	
102. 103		104. 105		106. 107		108. 109	
110. 111		112. 113		114. 115		116. 117	
118. 119		120. 121		122. 123		124. 125	
126. 127		128. 129		130. 131		132. 133	
134. 135		136. 137		138. 139		140. 141	
142. 143		144. 145		146. 147		148. 149	
150. 151		152. 153		154. 155		156. 157	
158. 159		160. 161		162. 163		164. 165	
166. 167		168. 169		170. 171		172. 173	
174. 175		176. 177		178. 179		180. 181	
182. 183		184. 185		186. 187		188. 189	
190. 191		192. 193		194. 195		196. 197	
198. 199		200. 201		202. 203		204. 205	
206. 207		208. 209		210. 211		212. 213	
214. 215		216. 217		218. 219		220. 221	
222. 223		224. 225		226. 227		228. 229	
230. 231		232. 233		234. 235		236. 237	
238. 239		240. 241		242. 243		244. 245	
246. 247		248. 249		250. 251		252. 253	
254. 255		256. 257		258. 259		260. 261	
262. 263		264. 265		266. 267		268. 269	
270. 271		272. 273		274. 275		276. 277	
278. 279		280. 281		282. 283		284. 285	
286. 287		288. 289		290. 291		292. 293	
294. 295		296. 297		298. 299		300. 301	
302. 303		304. 305		306. 307		308. 309	
310. 311		312. 313		314. 315		316. 317	
318. 319		320. 321		322. 323		324. 325	
326. 327		328. 329		330. 331		332. 333	
334. 335		336. 337		338. 339		340. 341	
342. 343		344. 345		346. 347		348. 349	
350. 351		352. 353		354. 355		356. 357	
358. 359		360. 361		362. 363		364. 365	
366. 367		368. 369		370. 371		372. 373	
374. 375		376. 377		378. 379		380. 381	
382. 383		384. 385		386. 387		388. 389	
390. 391		392. 393		394. 395		396. 397	
398. 399		400. 401		402. 403		404. 405	
406. 407		408. 409		410. 411		412. 413	
414. 415		416. 417		418. 419		420. 421	
422. 423		424. 425		426. 427		428. 429	
430. 431		432. 433		434. 435		436. 437	
438. 439		440. 441		442. 443		444. 445	
446. 447		448. 449		450. 451		452. 453	
454. 455		456. 457		458. 459		460. 461	
462. 463		464. 465		466. 467		468. 469	
470. 471		472. 473		474. 475		476. 477	
478. 479		480. 481		482. 483		484. 485	
486. 487		488. 489		490. 491		492. 493	
494. 495		496. 497		498. 499		500. 501	
502. 503		504. 505		506. 507		508. 509	
510. 511		512. 513		514. 515		516. 517	
518. 519		520. 521		522. 523		524. 525	
526. 527		528. 529		530. 531		532. 533	
534. 535		536. 537		538. 539		540. 541	
542. 543		544. 545		546. 547		548. 549	
550. 551		552. 553		554. 555		556. 557	
558. 559		560. 561		562. 563		564. 565	
566. 567		568. 569		570. 571		572. 573	
574. 575		576. 577		578. 579		580. 581	
582. 583		584. 585		586. 587		588. 589	
590. 591		592. 593		594. 595		596. 597	
598. 599		600. 601		602. 603		604. 605	
606. 607		608. 609		610. 611		612. 613	
614. 615		616. 617		618. 619		620. 621	
622. 623		624. 625		626. 627		628. 629	
630. 631		632. 633		634. 635		636. 637	
638. 639		640. 641		642. 643		644. 645	
646. 647		648. 649		650. 651		652. 653	
654. 655		656. 657		658. 659		660. 661	
662. 663		664. 665		666. 667		668. 669	
670. 671		672. 673		674. 675		676. 677	
678. 679		680. 681		682. 683		684. 685	
686. 687		688. 689		690. 691		692. 693	
694. 695		696. 697		698. 699		700. 701	
702. 703		704. 705		706. 707		708. 709	
710. 711		712. 713		714. 715		716. 717	
718. 719		720. 721		722. 723		724. 725	
726. 727		728. 729		730. 731		732. 733	
734. 735		736. 737		738. 739		740. 741	
742. 743		744. 745		746. 747		748. 749	
750. 751		752. 753		754. 755		756. 757	
758. 759		760. 761		762. 763		764. 765	
766. 767		768. 769		770. 771		772. 773	
774. 775		776. 777		778. 779		780. 781	
782. 783		784. 785		786. 787		788. 789	
790. 791		792. 793		794. 795		796. 797	
798. 799		800. 801		802. 803		804. 805	
806. 807		808. 809		810. 811		812. 813	
814. 815		816. 817		818. 819		820. 821	
822. 823		824. 825		826. 827		828. 829	
830. 831		832. 833		834. 835		836. 837	
838. 839		840. 841		842. 843		844. 845	
846. 847		848. 849		850. 851		852. 853	
854. 855		856. 857		858. 859		860. 861	
862. 863		864. 865		866. 867		868. 869	
870. 871		872. 873		874. 875		876. 877	
878. 879		880. 881		882. 883		884. 885	
886. 887		888. 889		890. 891		892. 893	
894. 895		896. 897		898. 899		900. 901	
902. 903		904. 905		906. 907		908. 909	
910. 911		912. 913		914. 915		916. 917	
918. 919		920. 921		922. 923		924. 925	
926. 927		928. 929		930. 931		932. 933	
934. 935		936. 937		938. 939		940. 941	
942. 943		944. 945		946. 947		948. 949	
950. 951		952. 953		954. 955		956. 957	
958. 959		960. 961		962. 963		964. 965	
966. 967		968. 969		970. 971		972. 973	
974. 975		976. 977		978. 979		980. 981	
982. 983		984. 985		986. 987		988. 989	
990. 991		992. 993		994. 995		996. 997	
998. 999		1000. 1001		1002. 1003		1004. 1005	
1006. 1007		1008. 1009		1010. 1011		1012. 1013	
1014. 1015		1016. 1017		1018. 1019		1020. 1021	
1022. 1023		1024. 1025		1026. 1027		1028. 1029	
1030. 1031		1032. 1033		1034. 1035		1036. 1037	
1038. 1039		1040. 1041		1042. 1043		1044. 1045	
1046. 1047		1048. 1049		1050. 1051		1052. 1053	
1054. 1055		1056. 1057		1058. 1059		1060. 1061	
1062. 1063		1064. 1065		1066. 1067		1068. 1069	
1070. 1071		1072. 1073		1074. 1075		1076. 1077	
1078. 1079		1080. 1081		1082. 1083		1084. 1085	
1086. 1087		1088. 1089		1090. 1091		1092. 1093	
1094. 1095		1096. 1097		1098. 1099		1100. 1101	
1102. 1103		1104. 1105		1106. 1107		1108. 1109	
1110. 1111		1112. 1113		1114. 1115		1116. 1117	
1118. 1119		1120. 1121		1122. 1123		1124. 1125	
1126. 1127		1128. 1129		1130. 1131		1132. 1133	
1134. 1135		1136. 1137		1138. 1139		1140. 1141	
1142. 1143		1144. 1145		1146. 1147		1148. 1149	
1150. 1151		1152. 1153		1154. 1155		1156. 1157	
1158. 1159		1160. 1161		1162. 1163		1164. 1165	
1166. 1167		1168. 1169		1170. 1171		1172. 1173	
1174. 1175		1176. 1177		1178. 1179		1180. 1181	
1182. 1183		1184. 1185		1186. 1187		1188. 1189	
1190. 1191		1192. 1193		1194. 1195		1196. 1197	
1198. 1199		1200. 1201		1202. 1203		1204. 1205	
1206. 1207		1208. 1209		1210. 1211		1212. 1213	
1214. 1215		1216. 1217		1218. 1219		1220. 1221	
1222. 1223		1224. 1225		1226. 1227		1228. 1229	
1230. 1231		1232. 1233		1234. 1235		1236. 1237	
1238. 1239		1240. 1241		1242. 1243		1244. 1245	
1246. 1247		1248. 1249		1250. 1251		1252. 1253	
1254. 1255		1256. 1257		1258. 1259		1260. 1261	
1262. 1263		1264. 1265		1266. 1267		1268.	



CONEXXENCE® (denosumab-bnht) offers resources to help your patients start and stay on prescribed therapy

We are dedicated to providing your patients
with ongoing support to help them access
Fresenius Kabi medications as prescribed.

Contact your Account Manager to
connect with a Field Reimbursement
Manager for the latest payer coverage
for patients and assistance with
billing and coding.



References: 1. CONEXXENCE®. Prescribing information. Fresenius Kabi, LLC; 2025. 2. Centers for Medicare & Medicaid Services. ICD Code Lists: Valid ICD-10 List [excel file]. <https://www.cms.gov/medicare/coordination-benefits-recovery/overview/icd-code-lists>. Page last modified October 29, 2024. Accessed January 10, 2025. 3. Centers for Medicare & Medicaid Services. HCPCS Application Summaries and Coding Determinations: Second Quarter, 2025 HCPCS Coding Cycle (Drugs and Biologicals). Published July 7, 2025. <https://www.cms.gov/files/document/2025-hcpcs-application-summary-quarter-2-2025-drugs-and-biologicals-posted-07-7-2025.pdf>. Accessed August 12, 2025. 4. Centers for Medicare & Medicaid Services. HCPCS Quarterly Update: January 2025 Alpha-Numeric HCPCS Files [zip file]. <https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system/quarterly-update>. Page last modified December 17, 2024. Accessed January 10, 2025. 5. Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual. Chapter 17: Drugs and Biologicals. <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c17.pdf>. Revised February 15, 2024. Accessed January 10, 2025. 6. Centers for Medicare & Medicaid Services. Medicare Part B inflation rebate guidance: Use of the 340B Modifier. <https://www.cms.gov/files/document/min4800856-medicare-part-b-inflation-rebate-guidance-use-340b-modifier.pdf>. Accessed January 10, 2025. 7. American Medical Association. CPT® code 96372: Injection of drug/substance under skin or into muscle. American Medical Association. Published January 1, 2025. <https://www.ama-assn.org/practice-management/cpt/cpt-code-96372-injection-drugsubstance-under-skin-or-muscle>. Accessed April 28, 2025. 8. American Academy of Professional Coders. CPT® Code 96401 in section: Chemotherapy and Other Highly Complex Biologic Agent Administration. AAPC. <https://www.aapc.com/codes/cpt-codes/96401>. Accessed May 8, 2025. 9. Medicare claims processing manual, Chapter 26 - Completing and Processing Form CMS-1500 Data Set. cms.gov. <https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/clm104c26.pdf>. Accessed January 15, 2025. 10. Medicare claims processing manual, Chapter 25 - Completing and Processing the Form CMS-1450 Data Set. cms.gov. <https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/clm104c25.pdf>. Accessed January 15, 2025.

Please see additional Important Safety Information throughout this brochure and click to see [Full Prescribing Information](#) and Medication Guide, including **Boxed Warning** for CONEXXENCE® (denosumab-bnht).